Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
10.34
+0.18 (1.77%)
At close: Dec 5, 2025, 4:00 PM EST
10.32
-0.02 (-0.19%)
After-hours: Dec 5, 2025, 5:01 PM EST
Entrada Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 61.52 | 210.78 | 129.01 | - | - | - | |
| Revenue Growth (YoY) | -71.42% | 63.38% | - | - | - | - | |
| Cost of Revenue | 141.72 | 125.31 | 99.88 | 66.61 | 35.93 | - | |
| Gross Profit | -80.2 | 85.48 | 29.13 | -66.61 | -35.93 | - | |
| Selling, General & Admin | 41.36 | 38.47 | 32.29 | 30.64 | 15.2 | 5.57 | |
| Research & Development | - | - | - | - | - | 21.1 | |
| Operating Expenses | 41.36 | 38.47 | 32.29 | 30.64 | 15.2 | 26.67 | |
| Operating Income | -121.56 | 47.01 | -3.16 | -97.25 | -51.13 | -26.67 | |
| Interest & Investment Income | 17.06 | 19.47 | 15.22 | 2.63 | 0.04 | 0.16 | |
| EBT Excluding Unusual Items | -104.49 | 66.49 | 12.06 | -94.62 | -51.08 | -26.5 | |
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.07 | -0.02 | |
| Pretax Income | -104.49 | 66.49 | 12.06 | -94.62 | -51.16 | -26.52 | |
| Income Tax Expense | -1.04 | 0.86 | 18.74 | - | - | - | |
| Net Income | -103.46 | 65.63 | -6.69 | -94.62 | -51.16 | -26.52 | |
| Net Income to Common | -103.46 | 65.63 | -6.69 | -94.62 | -51.16 | -26.52 | |
| Shares Outstanding (Basic) | 41 | 37 | 33 | 31 | 6 | 1 | |
| Shares Outstanding (Diluted) | 41 | 39 | 33 | 31 | 6 | 1 | |
| Shares Change (YoY) | 15.95% | 18.01% | 5.62% | 399.27% | 467.09% | 18.45% | |
| EPS (Basic) | -2.51 | 1.76 | -0.20 | -3.02 | -8.16 | -24.00 | |
| EPS (Diluted) | -2.52 | 1.68 | -0.20 | -3.02 | -8.16 | -24.00 | |
| Free Cash Flow | -129.8 | -44.72 | 134.19 | -96.67 | -55.44 | -27.89 | |
| Free Cash Flow Per Share | -3.15 | -1.15 | 4.06 | -3.09 | -8.85 | -25.23 | |
| Gross Margin | -130.36% | 40.55% | 22.58% | - | - | - | |
| Operating Margin | -197.59% | 22.30% | -2.45% | - | - | - | |
| Profit Margin | -168.17% | 31.14% | -5.18% | - | - | - | |
| Free Cash Flow Margin | -210.98% | -21.21% | 104.01% | - | - | - | |
| EBITDA | -117.36 | 50.78 | -0.32 | -95.35 | -50.01 | -26.34 | |
| EBITDA Margin | -190.76% | 24.09% | -0.25% | - | - | - | |
| D&A For EBITDA | 4.2 | 3.77 | 2.84 | 1.9 | 1.12 | 0.33 | |
| EBIT | -121.56 | 47.01 | -3.16 | -97.25 | -51.13 | -26.67 | |
| EBIT Margin | -197.59% | 22.30% | -2.45% | - | - | - | |
| Effective Tax Rate | - | 1.29% | 155.45% | - | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.